Mod­er­na pulls BLA for its Covid-flu shot: The com­pa­ny sug­gest­ed on its most re­cent … Get free access to a limited ...

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according ...

ReproNovo raises $65M for trials of leflutrozole and nolasiban in reproductive health. CEO Jean Marie Duvall plans Phase 2 ...

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US ...

Senate Democrats grilled Kennedy on Tuesday over gaps in his budget and funding cuts that have halted or eliminated key ...

Biotech execs express concerns over FDA changes, NIH cuts, and Trump's tariffs. Industry confidence low amid poor funding ...

SV Health closes $269M dementia fund, Schrödinger cuts 60 jobs, Beckley Psytech's BPL-003 shows promise in depression, and ...

Calibrate names Rob Rebak as new CEO, replacing Rob MacNaughton, amid executive changes. CFO and Chief Clinical Officer also ...

Tourmaline Bio's drug pacibekitug reduced inflammation markers in heart disease study; company plans FDA talks for Phase 3 ...